Free Trial

Ameriflex Group Inc. Invests $464,000 in Merck & Co., Inc. (NYSE:MRK)

Merck & Co., Inc. logo with Medical background

Ameriflex Group Inc. acquired a new position in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 4,698 shares of the company's stock, valued at approximately $464,000.

A number of other institutional investors have also recently added to or reduced their stakes in MRK. Norges Bank acquired a new position in Merck & Co., Inc. during the fourth quarter worth about $3,479,799,000. Bank of New York Mellon Corp increased its position in shares of Merck & Co., Inc. by 29.7% in the fourth quarter. Bank of New York Mellon Corp now owns 24,213,537 shares of the company's stock valued at $2,408,763,000 after buying an additional 5,550,824 shares in the last quarter. Wellington Management Group LLP increased its position in shares of Merck & Co., Inc. by 6.5% in the fourth quarter. Wellington Management Group LLP now owns 80,742,030 shares of the company's stock valued at $8,032,217,000 after buying an additional 4,932,647 shares in the last quarter. Northern Trust Corp increased its position in shares of Merck & Co., Inc. by 16.8% in the fourth quarter. Northern Trust Corp now owns 31,377,107 shares of the company's stock valued at $3,121,395,000 after buying an additional 4,511,742 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its position in shares of Merck & Co., Inc. by 63.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 11,577,535 shares of the company's stock valued at $1,151,642,000 after buying an additional 4,480,007 shares in the last quarter. Hedge funds and other institutional investors own 76.07% of the company's stock.

Merck & Co., Inc. Trading Down 1.8%

NYSE MRK traded down $1.42 during trading hours on Wednesday, hitting $76.17. 12,271,265 shares of the company's stock were exchanged, compared to its average volume of 12,567,465. The business's 50 day moving average is $81.09 and its 200-day moving average is $91.05. Merck & Co., Inc. has a 12-month low of $73.31 and a 12-month high of $134.63. The firm has a market capitalization of $191.27 billion, a P/E ratio of 11.32, a price-to-earnings-growth ratio of 0.77 and a beta of 0.43. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.15 and a current ratio of 1.36.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The company reported $2.22 EPS for the quarter, beating the consensus estimate of $2.16 by $0.06. Merck & Co., Inc. had a return on equity of 45.35% and a net margin of 26.67%. The company had revenue of $15.53 billion during the quarter, compared to analysts' expectations of $15.59 billion. During the same quarter in the previous year, the business earned $2.07 EPS. The firm's revenue was down 1.6% on a year-over-year basis. As a group, analysts anticipate that Merck & Co., Inc. will post 9.01 EPS for the current fiscal year.

Merck & Co., Inc. declared that its board has approved a stock buyback plan on Tuesday, January 28th that allows the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization allows the company to buy up to 4.1% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company's board believes its stock is undervalued.

Merck & Co., Inc. Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 8th. Stockholders of record on Monday, June 16th will be paid a dividend of $0.81 per share. The ex-dividend date of this dividend is Monday, June 16th. This represents a $3.24 annualized dividend and a dividend yield of 4.25%. Merck & Co., Inc.'s dividend payout ratio is presently 47.16%.

Insider Activity

In related news, SVP Dalton E. Smart III sold 4,262 shares of the firm's stock in a transaction that occurred on Friday, April 25th. The shares were sold at an average price of $82.76, for a total value of $352,723.12. Following the transaction, the senior vice president now owns 7,778 shares in the company, valued at approximately $643,707.28. This trade represents a 35.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.09% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on MRK. Cantor Fitzgerald cut Merck & Co., Inc. from an "overweight" rating to a "cautious" rating in a research report on Tuesday, May 20th. Morgan Stanley lowered their price target on shares of Merck & Co., Inc. from $113.00 to $106.00 and set an "equal weight" rating on the stock in a research report on Wednesday, February 5th. TD Securities lowered Merck & Co., Inc. from a "buy" rating to a "hold" rating and reduced their target price for the company from $121.00 to $100.00 in a research note on Monday, February 10th. Deutsche Bank Aktiengesellschaft lowered Merck & Co., Inc. from a "buy" rating to a "hold" rating and reduced their target price for the company from $128.00 to $105.00 in a research note on Tuesday, February 18th. Finally, Guggenheim reaffirmed a "buy" rating and issued a $115.00 target price on shares of Merck & Co., Inc. in a research note on Thursday, April 17th. One analyst has rated the stock with a sell rating, twelve have given a hold rating, seven have assigned a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $109.19.

Check Out Our Latest Analysis on Merck & Co., Inc.

About Merck & Co., Inc.

(Free Report)

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

Featured Stories

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Should You Invest $1,000 in Merck & Co., Inc. Right Now?

Before you consider Merck & Co., Inc., you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merck & Co., Inc. wasn't on the list.

While Merck & Co., Inc. currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Free Today: Your Guide to Smarter Options Trades Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings Preview: HUGE Stock Move Ahead
These 5 Small Stocks Could Deliver Huge Returns
ACT FAST! Congress Is POURING Into This Stock

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines